{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T21:45:26Z","timestamp":1764020726188},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cyclosporine-A (CsA) is used to prevent acute graft-versus-host disease (aGvHD). European Society for Blood and Marrow transplantation (EBMT) recommends a CsA target serum concentration of 200\u2013300\u00a0\u00b5g\/L during the first month after allogeneic hematopoietic stem cell transplantation (HSCT). With this study, we investigated whether a median CsA concentration\u2009&gt;\u2009200\u00a0\u00b5g\/L (CsA<jats:sub>high<\/jats:sub>) the first month after HSCT, compared to\u2009\u2264\u2009200\u00a0\u00b5g\/L (CsA<jats:sub>low<\/jats:sub>), increased the relapse risk of acute myloid leukemia (AML), using unrelated donors (URD) and antithymocyte globulin (ATG). Data was collected from 157 patients with AML, transplanted 2010\u20132016. The cumulative incidence of relapse (CIR) at 60\u00a0months was 50% in the CsA<jats:sub>high<\/jats:sub> versus 32% in the CsA<jats:sub>low<\/jats:sub> group (p\u2009=\u20090.016). In univariate analysis, CsA<jats:sub>high<\/jats:sub> versus CsA<jats:sub>low<\/jats:sub> (p\u2009=\u20090.028), 10-unit increase of CsA as a continuous variable (p\u2009=\u20090.017) and high risk disease (p\u2009=\u20090.003) were associated with higher CIR. The results remained after adjusting for disease risk. Death following relapse occurred more frequently in the CsA<jats:sub>high<\/jats:sub> group (p\u2009=\u20090.0076). There were no significant differences in rates of aGvHD, chronic GvHD (cGvHD), EBV\/CMV-infections or overall survival (OS) between the two groups. In conclusion, we found that a median CsA concentration\u2009&gt;\u2009200\u00a0\u00b5g\/L, the first month after HSCT, results in higher CIR of AML when combined with ATG.<\/jats:p>","DOI":"10.1038\/s41598-023-50105-4","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T15:02:11Z","timestamp":1703084531000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Higher cyclosporine-A concentration increases the risk of relapse in AML following allogeneic stem cell transplantation from unrelated donors using anti-thymocyte globulin"],"prefix":"10.1038","volume":"13","author":[{"given":"Mikael","family":"Lisak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malin","family":"Nicklasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Palmason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stina","family":"Wichert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecila","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Ola","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Erik","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stig","family":"Lenhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats","family":"Brune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"50105_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.812207","volume":"11","author":"JA Webster","year":"2021","unstructured":"Webster, J. A., Luznik, L. & Gojo, I. Treatment of AML relapse after allo-HCT. Front. Oncol. 11, 812207. https:\/\/doi.org\/10.3389\/fonc.2021.812207 (2021).","journal-title":"Front. Oncol."},{"key":"50105_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2015.64.2405","volume":"34","author":"J Styczynski","year":"2016","unstructured":"Styczynski, J. et al. Impact of donor Epstein\u2013Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: A study from the acute leukemia and infectious diseases working parties of the European Society for Blood and Marrow Transplantation. J. Clin. Oncol. 34, 2212\u20132220. https:\/\/doi.org\/10.1200\/JCO.2015.64.2405 (2016).","journal-title":"J. Clin. Oncol."},{"key":"50105_CR3","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","volume":"53","author":"M Horowitz","year":"2018","unstructured":"Horowitz, M. et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant 53, 1379\u20131389. https:\/\/doi.org\/10.1038\/s41409-018-0171-z (2018).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai, S. et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: A report from the Center for International Blood and Marrow Transplant Research. Biol. Blood Marrow Transplant 21, 266\u2013274. https:\/\/doi.org\/10.1016\/j.bbmt.2014.10.021 (2015).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"50105_CR5","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","volume":"108","author":"CJ Fraser","year":"2006","unstructured":"Fraser, C. J. et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: A report from the Bone Marrow Transplant Survivor Study. Blood 108, 2867\u20132873. https:\/\/doi.org\/10.1182\/blood-2006-02-003954 (2006).","journal-title":"Blood"},{"key":"50105_CR6","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/jco.2010.33.7212","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard, J. R. et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J. Clin. Oncol. 29, 2230\u20132239. https:\/\/doi.org\/10.1200\/jco.2010.33.7212 (2011).","journal-title":"J. Clin. Oncol."},{"key":"50105_CR7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","volume":"28","author":"PJ Martin","year":"2010","unstructured":"Martin, P. J. et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J. Clin. Oncol. 28, 1011\u20131016. https:\/\/doi.org\/10.1200\/JCO.2009.25.6693 (2010).","journal-title":"J. Clin. Oncol."},{"key":"50105_CR8","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00277-015-2452-6","volume":"94","author":"F Ayuk","year":"2015","unstructured":"Ayuk, F. et al. Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria. Ann. Hematol. 94, 1727\u20131732. https:\/\/doi.org\/10.1007\/s00277-015-2452-6 (2015).","journal-title":"Ann. Hematol."},{"key":"50105_CR9","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.3324\/haematol.2011.049841","volume":"96","author":"J Pidala","year":"2011","unstructured":"Pidala, J. et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica 96, 1678\u20131684. https:\/\/doi.org\/10.3324\/haematol.2011.049841 (2011).","journal-title":"Haematologica"},{"key":"50105_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbmt.2009.08.010","volume":"16","author":"F Malard","year":"2010","unstructured":"Malard, F. et al. Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation. Biol. Blood Marrow Transplant 16, 28\u201334. https:\/\/doi.org\/10.1016\/j.bbmt.2009.08.010 (2010).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"50105_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/sj.bmt.1704213","volume":"32","author":"P Martin","year":"2003","unstructured":"Martin, P. et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 32, 777\u2013784. https:\/\/doi.org\/10.1038\/sj.bmt.1704213 (2003).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR12","first-page":"461","volume":"7","author":"D Przepiorka","year":"1991","unstructured":"Przepiorka, D. et al. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 7, 461\u2013465 (1991).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00277-018-3577-1","volume":"98","author":"M Bianchi","year":"2019","unstructured":"Bianchi, M. et al. Cyclosporine levels > 195 mug\/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Ann. Hematol. 98, 971\u2013977. https:\/\/doi.org\/10.1007\/s00277-018-3577-1 (2019).","journal-title":"Ann. Hematol."},{"key":"50105_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/bmt.2013.139","volume":"49","author":"JR Rogosheske","year":"2014","unstructured":"Rogosheske, J. R. et al. Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival. Bone Marrow Transplant 49, 122\u2013125. https:\/\/doi.org\/10.1038\/bmt.2013.139 (2014).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/620682","volume":"2014","author":"I Garcia Cadenas","year":"2014","unstructured":"Garcia Cadenas, I. et al. Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. Mediators Inflamm. 2014, 620682. https:\/\/doi.org\/10.1155\/2014\/620682 (2014).","journal-title":"Mediators Inflamm."},{"key":"50105_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41409-022-01598-6","volume":"57","author":"J Heritier","year":"2022","unstructured":"Heritier, J. et al. Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: A single-center cohort study. Bone Marrow Transplant 57, 613\u2013619. https:\/\/doi.org\/10.1038\/s41409-022-01598-6 (2022).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14732","volume":"36","author":"ACF Kwan","year":"2022","unstructured":"Kwan, A. C. F. et al. Toward optimization of cyclosporine concentration target to prevent acute graft-versus-host disease following myeloablative allogeneic stem cell transplant. Clin. Transplant 36, e14732. https:\/\/doi.org\/10.1111\/ctr.14732 (2022).","journal-title":"Clin. Transplant"},{"key":"50105_CR18","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack, O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: Updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 7, e157\u2013e167. https:\/\/doi.org\/10.1016\/S2352-3026(19)30256-X (2020).","journal-title":"Lancet Haematol."},{"key":"50105_CR19","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1182\/blood.V77.7.1423.1423","volume":"77","author":"A Bacigalupo","year":"1991","unstructured":"Bacigalupo, A. et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77, 1423\u20131428 (1991).","journal-title":"Blood"},{"key":"50105_CR20","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1182\/blood.V95.5.1572.005k12_1572_1579","volume":"95","author":"F Locatelli","year":"2000","unstructured":"Locatelli, F. et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: Results of a randomized trial. Blood 95, 1572\u20131579 (2000).","journal-title":"Blood"},{"key":"50105_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25131","author":"A Bacigalupo","year":"2018","unstructured":"Bacigalupo, A. et al. High vs low dose cyclosporine-A, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study. Am. J. Hematol. https:\/\/doi.org\/10.1002\/ajh.25131 (2018).","journal-title":"Am. J. Hematol."},{"key":"50105_CR22","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3324\/haematol.2009.013920","volume":"95","author":"C Craddock","year":"2010","unstructured":"Craddock, C. et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 95, 989\u2013995. https:\/\/doi.org\/10.3324\/haematol.2009.013920 (2010).","journal-title":"Haematologica"},{"key":"50105_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bmt.1704758","volume":"35","author":"A Bacigalupo","year":"2005","unstructured":"Bacigalupo, A. Antilymphocyte\/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 35, 225\u2013231. https:\/\/doi.org\/10.1038\/sj.bmt.1704758 (2005).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger, N. et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N. Engl. J. Med. 374, 43\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1506002 (2016).","journal-title":"N. Engl. J. Med."},{"key":"50105_CR25","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s1470-2045(15)00462-3","volume":"17","author":"I Walker","year":"2016","unstructured":"Walker, I. et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: A randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 17, 164\u2013173. https:\/\/doi.org\/10.1016\/s1470-2045(15)00462-3 (2016).","journal-title":"Lancet Oncol."},{"key":"50105_CR26","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1200\/jco.20.00150","volume":"38","author":"YJ Chang","year":"2020","unstructured":"Chang, Y. J. et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: A multicenter, open-label, randomized controlled study. J. Clin. Oncol. 38, 3367\u20133376. https:\/\/doi.org\/10.1200\/jco.20.00150 (2020).","journal-title":"J. Clin. Oncol."},{"key":"50105_CR27","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/bmt.2012.45","volume":"47","author":"T Ruutu","year":"2012","unstructured":"Ruutu, T. et al. Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: A survey of centre strategies by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 47, 1459\u20131464. https:\/\/doi.org\/10.1038\/bmt.2012.45 (2012).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR28","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JOP.2016.014456","volume":"12","author":"N Kroger","year":"2016","unstructured":"Kroger, N. Outcome improvement after allogeneic stem-cell transplantation in myelofibrosis. J. Oncol. Pract. 12, 629\u2013631. https:\/\/doi.org\/10.1200\/JOP.2016.014456 (2016).","journal-title":"J. Oncol. Pract."},{"key":"50105_CR29","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","volume":"10","author":"J Finke","year":"2009","unstructured":"Finke, J. et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: A randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 10, 855\u2013864. https:\/\/doi.org\/10.1016\/S1470-2045(09)70225-6 (2009).","journal-title":"Lancet Oncol."},{"key":"50105_CR30","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1200\/jco.2017.75.8177","volume":"35","author":"RJ Soiffer","year":"2017","unstructured":"Soiffer, R. J. et al. Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation. J. Clin. Oncol. 35, 4003\u20134011. https:\/\/doi.org\/10.1200\/jco.2017.75.8177 (2017).","journal-title":"J. Clin. Oncol."},{"key":"50105_CR31","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s41409-017-0043-y","volume":"53","author":"R Devillier","year":"2018","unstructured":"Devillier, R. et al. Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: A report from the acute leukemia working party of European Group of Bone Marrow Transplantation. Bone Marrow Transplant 53, 431\u2013437. https:\/\/doi.org\/10.1038\/s41409-017-0043-y (2018).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR32","unstructured":"Nationellt V\u00e5rdprogram f\u00f6r AML; Version 7.0. (Regionala Cancercentrum i Samverkan, 2022)."},{"key":"50105_CR33","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans, H. M. et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 53, 1401\u20131415. https:\/\/doi.org\/10.1038\/s41409-018-0204-7 (2018).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia, M. H. et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol. Blood Marrow Transplant 21, 389\u2013401. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001 (2015).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"50105_CR35","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo, A. et al. Defining the intensity of conditioning regimens: Working definitions. Biol. Blood Marrow Transplant 15, 1628\u20131633. https:\/\/doi.org\/10.1016\/j.bbmt.2009.07.004 (2009).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"50105_CR36","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-x","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper, M. & Smith, T. L. A note on quantifying follow-up in studies of failure time. Control Clin. Trials 17, 343\u2013346. https:\/\/doi.org\/10.1016\/0197-2456(96)00075-x (1996).","journal-title":"Control Clin. Trials"},{"key":"50105_CR37","unstructured":"Sahtish, N. W. C-L Ally. In PharmaSUG 2019\u2014Paper ST-81-5 (Philadelphia, 2019)."},{"key":"50105_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1158\/1078-0432.ccr-06-1210","volume":"13","author":"HT Kim","year":"2007","unstructured":"Kim, H. T. Cumulative incidence in competing risks data and competing risks regression analysis. Clin. Cancer Res. 13, 559\u2013565. https:\/\/doi.org\/10.1158\/1078-0432.ccr-06-1210 (2007).","journal-title":"Clin. Cancer Res."},{"key":"50105_CR39","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 1141\u20131154 (1988).","journal-title":"Ann. Stat."},{"key":"50105_CR40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"50105_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.22004\/ag.econ.127346","volume":"9","author":"PCR Lambert","year":"2009","unstructured":"Lambert, P. C. R. Further development of flexible parametric models for survival analysis. Stata J. 9, 265\u2013290. https:\/\/doi.org\/10.22004\/ag.econ.127346 (2009).","journal-title":"Stata J."},{"key":"50105_CR42","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41409-022-01604-x","volume":"57","author":"JR Passweg","year":"2022","unstructured":"Passweg, J. R. et al. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: A report from the EBMT activity survey. Bone Marrow Transplant 57, 742\u2013752. https:\/\/doi.org\/10.1038\/s41409-022-01604-x (2022).","journal-title":"Bone Marrow Transplant"},{"key":"50105_CR43","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan, N. et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: A center for international blood and marrow transplant research study. Biol. Blood Marrow Transplant 21, 454\u2013459. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.007 (2015).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"50105_CR44","doi-asserted-by":"publisher","first-page":"771e771-771e710","DOI":"10.1016\/j.jtct.2021.05.011","volume":"27","author":"C Zuanelli Brambilla","year":"2021","unstructured":"Zuanelli Brambilla, C. et al. Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy. Transplant Cell Ther. 27, 771e771\u2013771e710. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.011 (2021).","journal-title":"Transplant Cell Ther."},{"key":"50105_CR45","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354\u2013365. https:\/\/doi.org\/10.1182\/blood-2009-11-254441 (2010).","journal-title":"Blood"},{"key":"50105_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2015-07-604496","volume":"127","author":"D Grimwade","year":"2016","unstructured":"Grimwade, D., Ivey, A. & Huntly, B. J. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127, 29\u201341. https:\/\/doi.org\/10.1182\/blood-2015-07-604496 (2016).","journal-title":"Blood"},{"key":"50105_CR47","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood-2006-10-043299","volume":"110","author":"MS Tallman","year":"2007","unstructured":"Tallman, M. S. et al. Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission. Blood 110, 409\u2013417. https:\/\/doi.org\/10.1182\/blood-2006-10-043299 (2007).","journal-title":"Blood"},{"key":"50105_CR48","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152. https:\/\/doi.org\/10.1056\/NEJMra1406184 (2015).","journal-title":"N. Engl. J. Med."},{"key":"50105_CR49","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.bbmt.2004.10.008","volume":"11","author":"R Wong","year":"2005","unstructured":"Wong, R. et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol. Blood Marrow Transplant 11, 108\u2013114. https:\/\/doi.org\/10.1016\/j.bbmt.2004.10.008 (2005).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"50105_CR50","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb, H. J. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371\u20134383. https:\/\/doi.org\/10.1182\/blood-2008-03-077974 (2008).","journal-title":"Blood"},{"key":"50105_CR51","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand, P. et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123, 3664\u20133671. https:\/\/doi.org\/10.1182\/blood-2014-01-552984 (2014).","journal-title":"Blood"},{"key":"50105_CR52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009159.pub2","author":"S Theurich","year":"2012","unstructured":"Theurich, S. et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD009159.pub2 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"50105_CR53","doi-asserted-by":"publisher","unstructured":"Bjork, J. et al. Revised equations for estimating glomerular filtration rate based on the Lund-Malm\u00f6 Study cohort. Scand J Clin Lab Invest 71, 232\u2013239. https:\/\/doi.org\/10.3109\/00365513.2011.557086 (2011).","DOI":"10.3109\/00365513.2011.557086"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50105-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50105-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T15:06:35Z","timestamp":1703084795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-50105-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["50105"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-50105-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"22 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests. ML received funding from Blodcancerf\u00f6rbundet, a non-profit patient organisation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22777"}}